Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Aerobit is a smart inhaler, a tool for tracking medication use that records each time inhalers are taken and comes in a variety of cool toy designs. Built in sensors can even tell if the inhaler has been shaken correctly.
days to go:
Expired
investment:
£116,960
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go:
Expired
investment:
Withheld
Viritech is a clean technology engineering company that is using F1-derived engineering to develop hydrogen powertrain solutions and related technologies for the automotive, aerospace, marine and distributed power industries. Viritech asserts that the Hydrogen Council forecasts that hydrogen will meet 18% of global energy demand by 2050. It aims to capture this demand through its technologies. Viritech argues that its location in MIRA Technology Park allows it access to R&D facilities used by many of the world's major automotive manufacturers, allowing it to scale its resources to meet the demands of every type of project. Viritech will use the investment to produce test hydrogen tanks, build the Apricale hypercar, complete designs for a Heavy Goods Vehicle (HGV), Sport Utility Vehicle (SUV) and a power generator, plan a larger raise and listing on AQuis Stock Exchange (AQSE) in 2022, and eventually commercialise its technology with its partner.
days to go:
Expired
investment:
£726,807
Trecento Diagnostics, with the help of a molecular testing system complete, they are now ready to launch a patent-pending collection device named HygieCatch®. It is a non-invasive, needle-free examination, in the vet practice providing DNA extraction from urine onsite with a report within 40 minutes of extraction of the sample. The company has identified partners in the UAE and US and is also in early-stage discussions with UK vet practices. Furthermore, for the purpose of commercialisation of HygieCatch & the technology used, alongside addition of new tests including Lyme disease the company is planning to raise its capital.
days to go:
Expired
investment:
£167,910
A medical condition management platform allowing clinicians to create their own app to improve a patient's health whilst reducing costs. Living With develops smart apps specific to a person's condition, they currently have 3 products with another in the development stage. Their primary app, Squeezy, is the top paid medical app in the UK that helps patients with their pelvic floor exercises. Other apps, allow clinicians to monitor a patient's bowel and bladder health, as well as those with rheumatoid arthritis. These apps are already in use at multiple NHS Trusts and clinics.
Funds are being raised to complete development of their apps to help those with lupus and lung cancer, in addition to further developing their existing products. The company aims to have thousands of apps that will be available worldwide to provide self-service treatment at any time. Living With is expecting to earn £1.07m in revenue by the end of March 2019.
days to go:
Expired
investment:
£250,000
Creative Hub is a fast-growing cloud software platform for creative people to store, share files, and collaborate on projects. The collaboration tools also allow users to chat in real-time, and add comments on images, allowing creative teams to work faster and deliver better results. Creative Hub enables users to order professional art & photographic prints, or physical 3D prints, which are produced at its print production facilities in London(UK) and Dusseldorf (Germany). The platform currently has 40,000 active users which are growing day by day. With the investment, the company will drive growth through marketing and launch its New York production facility.
days to go:
Expired
investment:
£286,992
Advanced Blast & Ballistic Systems (ABBS) develops patented systems to counteract the forces an armoured vehicle sustains when a mine or Improvised Explosive Device (IED) explodes under it. ABBS asserts that mines and IEDs accounted for over 80% of UK and US army casualties in Iraq and Afghanistan. ABBS argues that its systems can reverse this scenario. It aspires to become a contender in the $20 billion armoured vehicle protection market. The company has been tasked by the European Union Aviation Safety Agency (EASA) and European Organisation for Civil Aviation Equipment (EUROCAE) to draft safety regulations for emergency descent arrest systems. It also holds multiple patents for its proven Vehicle Global Acceleration Mitigation (VGAM) vehicle mine protection system and has a patent pending for a Zero-Zero Crash Prevention (ZZCP) system for light aircraft and electric Vertical Takeoff and Landing (eVTOLs) systems. ABBS will use the investment for marketing, boosting R&D, and maintaining and expanding its IP/patent portfolio.
days to go:
Expired
investment:
£297,534
CrowdProperty is a specialist property project lending platform that matches quality property professionals undertaking quality property projects with institutional/private investors of capital for value-creating property projects. It seeks to ensure profits for borrowers, lenders, the under-supplied UK housing environment, and the UK economy through its business model. The company claims to have recently closed a £300 million funding line from a global asset manager. It has lent upwards of £140 million with £180 million+ originated facilities, gained recognition by Deloitte Fast50 and FT1000 as a 'High Growth Business', and built a proprietary and scalable technology platform. CrowdProperty has also launched CrowdProperty Australia, leveraging its asset-class expertise, scalable proprietary technology and IP from the UK business in the Australian market. The company states it will use the investment to grow its property team, evolve its technology platform further, acquire more customers, and grow its business.
days to go:
Expired
investment:
£1,815,319
Rightangled is a DNA testing company backed by NHS that delivers services to consumers and medical/fitness specialists. The company is a full CQC healthcare provider license that has achieved registration with Bupa, a leading medical insurance company. The company is now planning to move into AI with a solid database. Rightangled has received excellent customer reviews with 5* on Google and 4.5* on Trustpilot. With the proceeds, the company will seek to launch its application, create a strong AI central system, and grow into new markets (US& UAE).
days to go:
Expired
investment:
£311,690
